Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301670 | 1.00 | MGAM (0.48) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL7047649 | 0.91 | HMGCR (0.50) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL7041938 | 0.83 | HMGCR (0.58) | GAAHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL15944462 | 0.82 | HMGCR (0.68) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL17301671 | 0.80 | HMGCR (0.41) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL11422035 | 0.80 | HMGCR (0.41) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL18751330 | 0.79 | TSHR (0.42) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL11026137 | 0.79 | MGAM (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL16580102 | 0.78 | GAA (0.50) | MGAMGAASIMGAM2HMGCR | |
| SCHEMBL13059616 | 0.77 | TSHR (0.40) | MGAMGAASIMGAM2HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202758-A1 | CORE 2GLCNAC-T INHIBITORS | MS THERAPEUTICS LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-8197794-B2 | Core 2 GlcNAc-T inhibitors | MS THERAPEUTICS LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-7998943-B2 | Treating a subject in need of therapy for a condition involving detrimental activity of the enzyme Core 2 GlcNAc-T(Core 2-N-acetylglucosaminyl transferase) comprising administration of a steroid compound inhibitor thereof; multiple sclerosis; antiinflammatory, anticarcinogenic agents | BTG INTERNATIONAL LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-7998943-B2 | Treating a subject in need of therapy for a condition involving detrimental activity of the enzyme Core 2 GlcNAc-T(Core 2-N-acetylglucosaminyl transferase) comprising administration of a steroid compound inhibitor thereof; multiple sclerosis; antiinflammatory, anticarcinogenic agents | BTG INTERNATIONAL LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-20100256077-A1 | Core 2GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-20100048495-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048495-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20080182801-A1 | Core 2 glcnac-t inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202758-A1 | CORE 2GLCNAC-T INHIBITORS | CSGALNACT1, SACM1L, ENGASE | MGAM 311/4885GAA 26/4885SI 191/4885 |
| US-20100256077-A1 | Core 2GlcNAc-T inhibitors | CSGALNACT1, SACM1L, ENGASE | MGAM 261/4885GAA 27/4885SI 183/4885 |
| US-20100048495-A1 | Core 2 GlcNAc-T inhibitors III | CSGALNACT1, ENGASE, GALNT6 | MGAM 177/4885GAA 24/4885SI 126/4885 |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | CSGALNACT1, ENGASE, GALNT6 | MGAM 161/4885GAA 25/4885SI 127/4885 |
| US-20080182801-A1 | Core 2 glcnac-t inhibitors | CSGALNACT1, ENGASE, GALNT6 | MGAM 157/4885GAA 42/4885SI 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.